# New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma

> **NCT00933673** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 76 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** L-asp, DXM, IFO, VP-16, DDP

## Key facts

- **NCT ID:** NCT00933673
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2012-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933673, "New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00933673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*